Trials / Completed
CompletedNCT00256711
Phase II Iressa Versus Vinorelbine (INVITE)
A Randomised, Open Label, Parallel Group, Multi-Centre, Phase II Study of Progression Free Survival Comparing ZD1839 (IRESSA™) (250 MG Tablet) Versus Vinorelbine (30 MG/M2 Infusion) in Chemonaive, Elderly Patients With Locally Advanced (Stage IIIB) or Metastatic (Stage IV) NSCLC
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 192 (planned)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 70 Years
- Healthy volunteers
- Not accepted
Summary
This is a randomized, open label, parallel group, multi-centre, phase II study of progression free survival, comparing oral ZD1839 (IRESSA™) (250 mg tablet once daily) to vinorelbine 30 mg/m2 infusion on days 1 and 8 of a 21-day cycle) in chemonaïve, elderly patients with locally advanced (stage IIIB) or metastatic (stage IV) non-small cell lung cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Gefitinib | |
| DRUG | Vinorelbine |
Timeline
- Start date
- 2004-07-01
- Completion
- 2006-02-01
- First posted
- 2005-11-22
- Last updated
- 2009-04-23
Locations
55 sites across 10 countries: Australia, Brazil, Czechia, France, Germany, Italy, South Africa, South Korea, Taiwan, United Kingdom
Source: ClinicalTrials.gov record NCT00256711. Inclusion in this directory is not an endorsement.